Menu Search
Equities

Shin Nippon Biomedical Laboratories Ltd

YB3:MUN

Shin Nippon Biomedical Laboratories Ltd

Actions
  • Price (EUR)19.80
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+62.30%
  • Beta--
Data delayed at least 15 minutes, as of Mar 29 2023 07:02 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.

  • Revenue in JPY (TTM)21.17bn
  • Net income in JPY6.23bn
  • Incorporated1973
  • Employees994.00
  • Location
    Shin Nippon Biomedical Laboratories Ltd28F, St Luke's Tower, 8-1, Akashi-choCHUO-KU 104-0044JapanJPN
  • Phone+81 355655001
  • Fax+81 355656160
  • Websitehttps://www.snbl.co.jp/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		2395:TYO since
announced		Transaction
value
Ina Research IncDeal completed01 Jun 202201 Jun 2022Deal completed70.48%20.97m
Data delayed at least 20 minutes, as of Mar 29 2023 07:00 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.